Biotechnology company ImmunoMet Therapeutics Inc revealed on Monday the appointment of Dr Revati Shreeniwas as its chief medical officer.
As head of the medial department, Dr Shreeniwas will manage the clinical development programme for the company's lead investigational product Protein Complex 1 (PC1) inhibitor candidate, IM156, for idiopathic pulmonary fibrosis (IPF) and oncology indications.
Recently, Dr Shreeniwas has served on the faculty of Stanford University and Columbia Presbyterian Medical Center.
Previously, Dr Shreeniwas designed and implemented more than 50 US and international (Phase 1-4) clinical trials and been the clinical lead for regulatory interactions with the FDA and EMA.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients